文献速递造血干细胞移植与细胞治疗

急性移植物抗宿主病二线治疗后的结局预测

Prediction of outcomes after second-line treatment for acute graft-versus-host disease.
PubMed 文献 · Blood Adv · 2022-01-01

该研究分析了216例接受二线治疗的急性移植物抗宿主病患者的结局,6个月和12个月总生存率分别为59%和52%,无失败生存率分别为42%和37%,并建立了基于血清白蛋白、总胆红素、年龄及腹痛/4期肠道受累的6个月和12个月死亡预测模型。

要点

  • 6个月和12个月总生存率分别为59%和52%。
  • 6个月和12个月无失败生存率分别为42%和37%。
  • 预测模型纳入二线治疗开始时血清白蛋白、总胆红素、年龄及腹痛/4期肠道受累。

核心结论

  • 研究确定了急性移植物抗宿主病二线治疗后与死亡和失败相关的危险因素,提供了评估无失败生存和总生存的历史基准,并提出了可用于生成人群特异性基准的6个月和12个月死亡预测模型。

研究设计与样本

  • 研究纳入216例接受异基因造血细胞移植后因急性移植物抗宿主病接受二线治疗的患者,分析总生存和无失败生存,无失败生存的失败时间定义为死亡、复发或实施三线治疗中最早发生者,采用多变量Cox回归识别死亡和失败的危险因素,并推导6个月和12个月死亡的预测模型。

主要发现

  • 6个月和12个月总生存率的点估计分别为59%(95%置信区间[CI],52-65)和52%(95% CI,45-68)。
  • 6个月和12个月无失败生存率的点估计分别为42%(95% CI,35-48)和37%(95% CI,31-43)。
  • 6个月和12个月死亡的预测模型均纳入二线治疗开始时的血清白蛋白和总胆红素浓度、二线治疗开始时的患者年龄以及腹痛/4期肠道受累的组合。
  • 6个月死亡预测模型的乐观校正受试者工作特征曲线下面积和Brier评分分别为77.4和0.169,12个月死亡预测模型分别为80.0和0.169。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (GVHD) requiring second-line treatment represents a highly morbid complication of allogenic hematopoietic cell transplantation (HCT). Recent studies have defined short-term outcomes after second-line treatment for acute GVHD, but longer-term outcomes have not been well defined. We examined overall survival (OS) and failure-free-survival (FFS) of 216 patient who had HCT who received second-line treatment for acute GVHD. Failure time for FFS was defined as the earliest of death, relapse, or implementation of third-line treatment. Multivariable Cox regression was used to identify risk factors for mortality and failure, and predictive models were derived for 6- and 12-month mortality. Point estimates of OS at 6 and 12 months were 59% (95% confidence interval [CI], 52-65) and 52% (95% CI, 45-68), respectively. Point estimates of FFS at 6 and 12 months were 42% (95% CI, 35-48) and 37% (95% CI, 31-43), respectively. Predictive models for both end points included serum albumin and total bilirubin concentrations at the onset of second-line treatment, patient age at onset of second-line therapy, and a combination of abdominal pain/stage 4 gut involvement. Optimism-corrected areas under the receiver-operator characteristic curve and Brier scores were 77.4 and 0.169 for 6-month mortality, respectively, and 80.0 and 0.169 for 12-month mortality. We identify risk factors associated with mortality and failure after second-line treatment of acute GVHD, provide historical benchmarks for assessment of FFS and OS in other studies, and propose predictive models for 6- and 12-month mortality that could be used to generate population-specific benchmarks.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vo P, Gooley TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022. PMID: 35235948. doi:10.1182/bloodadvances.2021006220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。